Skip to content
10-Q

Quarterly Report

iTeos Therapeutics, Inc.

0000950170-24-057472

← back to feed
Filed
May 10, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · May 3, 2024 36.12M sh
Short Term Investments Q1 2024 · Mar 31, 2024 $302.5M
Short Term Investments Q1 2024 · Dec 31, 2023 $280.74M
Cash And Equivalents Q1 2024 · Mar 31, 2024 $146.65M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $251.18M
Current Liabilities Q1 2024 · Mar 31, 2024 $35.56M
Current Liabilities Q1 2024 · Dec 31, 2023 $40.01M
Total Liabilities Q1 2024 · Mar 31, 2024 $88.57M
Total Liabilities Q1 2024 · Dec 31, 2023 $92.36M
Current Assets Q1 2024 · Mar 31, 2024 $480.39M
Current Assets Q1 2024 · Dec 31, 2023 $550.65M
Total Assets Q1 2024 · Mar 31, 2024 $629.77M
Total Assets Q1 2024 · Dec 31, 2023 $667.59M
Revenue Q1 2024 · Mar 31, 2024 $0
Revenue Q1 2024 · Mar 31, 2023 $12.6M
Shares Diluted Q1 2024 · Mar 31, 2023 35.72M sh
Capex Q1 2024 · Mar 31, 2023 $119K
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$26.56M
Stockholders Equity Q1 2024 · Mar 31, 2023 $652.26M
Stockholders Equity Q1 2024 · Dec 31, 2022 $663.33M
Eps Diluted Q1 2024 · Mar 31, 2023 −$0.44
Eps Basic Q1 2024 · Mar 31, 2023 −$0.44
Sga Expense Q1 2024 · Mar 31, 2023 $11.93M
Rd Expense Q1 2024 · Mar 31, 2023 $25.6M
Net Income Q1 2024 · Mar 31, 2023 −$15.55M
Operating Income Q1 2024 · Mar 31, 2023 −$24.93M